Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(4.53)
# 128
Out of 4,479 analysts
18
Total ratings
66.67%
Success rate
19.67%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Reiterates: Neutral | n/a | $59.02 | - | 2 | Jun 18, 2024 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $42.05 | - | 2 | Jun 17, 2024 | |
| ADCT ADC Therapeutics | Initiates: Overweight | n/a | $3.48 | - | 1 | May 30, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $53.12 | - | 2 | May 9, 2024 | |
| TNGX Tango Therapeutics | Initiates: Overweight | n/a | $8.11 | - | 1 | Apr 4, 2024 | |
| RNA Avidity Biosciences | Initiates: Overweight | $60 | $38.80 | +54.64% | 1 | Mar 14, 2024 | |
| BIIB Biogen | Reiterates: Overweight | $311 | $228.82 | +35.91% | 2 | Feb 20, 2024 | |
| IMTX Immatics | Initiates: Overweight | n/a | $12.02 | - | 1 | Nov 2, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | n/a | $34.80 | - | 1 | Nov 2, 2023 | |
| BLUE bluebird bio | Initiates: Neutral | n/a | $0.92 | - | 1 | Oct 17, 2023 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $370 | $473.78 | -21.90% | 1 | Oct 17, 2023 | |
| EDIT Editas Medicine | Downgrades: Neutral | n/a | $4.54 | - | 1 | Oct 17, 2023 | |
| GTHX G1 Therapeutics | Initiates: Outperform | n/a | $2.45 | - | 1 | Jun 12, 2017 | |
| OVID Ovid Therapeutics | Initiates: Outperform | n/a | $0.77 | - | 1 | May 30, 2017 |
Incyte
Jun 18, 2024
Reiterates: Neutral
Price Target: n/a
Current: $59.02
Upside: -
Agios Pharmaceuticals
Jun 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $42.05
Upside: -
ADC Therapeutics
May 30, 2024
Initiates: Overweight
Price Target: n/a
Current: $3.48
Upside: -
CRISPR Therapeutics AG
May 9, 2024
Reiterates: Neutral
Price Target: n/a
Current: $53.12
Upside: -
Tango Therapeutics
Apr 4, 2024
Initiates: Overweight
Price Target: n/a
Current: $8.11
Upside: -
Avidity Biosciences
Mar 14, 2024
Initiates: Overweight
Price Target: $60
Current: $38.80
Upside: +54.64%
Biogen
Feb 20, 2024
Reiterates: Overweight
Price Target: $311
Current: $228.82
Upside: +35.91%
Immatics
Nov 2, 2023
Initiates: Overweight
Price Target: n/a
Current: $12.02
Upside: -
Immunocore Holdings
Nov 2, 2023
Initiates: Overweight
Price Target: n/a
Current: $34.80
Upside: -
bluebird bio
Oct 17, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.92
Upside: -
Vertex Pharmaceuticals
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $473.78
Upside: -21.90%
Editas Medicine
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.54
Upside: -
G1 Therapeutics
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.45
Upside: -
Ovid Therapeutics
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -